Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: Multi-institutional retrospective analysis

Gastric Cancer

Volumn 15, Issue 3, 2012, Pages 245-251

  Shitara, Kohei ^a   Morita, Satoshi ^b   Fujitani, Kazumasa ^c   Kadowaki, Shigenori ^d   Takiguchi, Nobuhiro ^e   Hirabayashi, Naoki ^f   Takahashi, Masazumi ^g   Takagi, Masakazu ^h   Tokunaga, Yukihiko ⁱ   Fukushima, Ryoji ^j   Munakata, Yasuhiro ^k   Nishikawa, Kazuhiro ^l   Takagane, Akinori ^m   Tanaka, Takaho ⁿ   Sekishita, Yoshiaki ^o   Sakamoto, Junichi ^p   Tsuburaya, Akira ^q  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c Department of Radiology   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f HIROSHIMA CITY ASA HOSPITAL   (Japan)

^g YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^h SHIZUOKA GENERAL HOSPITAL   (Japan)

ⁱ Japan Post   (Japan)

^j TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k Nagano Municipal Hospital   (Japan)

^l OSAKA GENERAL MEDICAL CENTER   (Japan)

^m HAKODATE GORYOUKAKU HOSPITAL   (Japan)

ⁿ Social Insurance Tagawa Hospital   (Japan)

^o Obihiro Kosei Hospital   (Japan)

^p NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q KANAGAWA CANCER CENTER   (Japan)

more..

Author keywords

Adjuvant chemotherapy; Gastric cancer; Recurrence; S 1

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE INTERVAL; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84865404729     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0101-x     Document Type: Article

References (29)

1. International Agency for Research on Cancer. GLOBOCAN. http://www-dep.iarc.fr/CancerMondial.htm (2008). Accessed April 2011
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluoro-uracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagoga-stric cancer. N Engl J Med. 2008;358:36-46.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-73.
6. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-53.
7. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715-20.
8. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-7.
9. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063-9.
10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357: 1810-20.
11. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. J Clin Oncol. 2011 Aug 15. [Epub ahead ofprint]
12. Shitara K, Muro K, Ura T, Takahari D, Yokota T, Sawaki A, et al. Chemotherapy for gastric cancer that recurs after adjuvant che-motherapy with S-1. Jpn J Clin Oncol. 2008;38:786-9.
13. Hasegawa H, Fujitani K, Kurokawa Y, Hirao M, Nakazuru S, Mita E, et al. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer. Chemotherapy. 2010;56:436-43.
14. Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, et al. Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer. 2011;14: 150-4.
15. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer. 2005;92:246-51.
16. Pujade-Lauraine E, Paraiso D, Cure H, Germann N, Lortholary A, Lucas V, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002;21:abstract 829.
17. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita N, Akatsuka S, et al. Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus. 2008;21:607-11.
18. De Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, et al. Definition of ox-aliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol. 2009;27:15s. (abstr 4024).
19. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 1994;21:1033-8.
20. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 1998;25:1915-24.
21. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Cooperative Study Group Trial (group B). Gan To Kagaku Ryoho. 1999;26:487-96.
22. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133-7.
23. Nakae S, Hirao M, Kishimoto T, Iijima S, Ishida H, Morimoto T, et al. Phase II study of bi-weekly CPT-11 + CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study). J Clin Oncol 2008;26 (May 20 suppl; abstr 4571).
24. Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, et al. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol. 2004;34:400-4.
25. Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol. 2009;39:315-20.
26. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/ doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol. 2008;38:176-81.
27. Ono A, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, et al. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotec-an + cisplatin or fluorouracil (except S-1). Jpn J Clin Oncol. 2009;39:332-5.
28. Yamamoto D, Yoshida H, Iwase S, Odagiri H, Kitamura K. TS-1 in patients with capecitabine-resistant breast cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 1103).
29. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.